Optimization of glycemic control should be a target for therapy
We show that the cardioprotective actions of GLP-1(2836) do not depend on a functional transmembrane GLP-1R but rather are mediated intracellularly through type 10 soluble adenylyl cyclase (sAC), accompanied by increased cAMP levels, protein kinase A (PKA) activation, and endothelial nitric oxide synthase (eNOS) phosphorylation
The FDA approved it on April 1, 2026, for adults with obesity or adults who are overweight and have at least one weight-related health condition such as high blood pressure, high cholesterol, or type 2 diabetes
Which Drug Is Better for Fatty Liver Disease
nausea or abdominal distress
S., Chong, P., and Rashid, P